1. HIV Update 2018: A Front Row Seat

3. Introduction

4. D/C/F/TAF Single-Tablet Regimen in Treatment-Naive Patients: AMBER

5. D/C/F/TAF Single-Tablet Regimen in Treatment-Naive Patients: AMBER Efficacy

6. D/C/F/TAF Single-Tablet Regimen in Treatment-Naive Patients: AMBER Safety

7. Bictegravir Coformulated With F/TAF in FDC vs DTG +F/TAF in Treatment-naive HIV-1-Positive Adults

8. Bictegravir Coformulated With F/TAF in FDC vs DTG +F/TAF in Treatment-Naive HIV-1-Positive Adults: Efficacy

9. Bictegravir Coformulated With F/TAF in FDC vs DTG +F/TAF in Treatment-Naive HIV-1-Positive Adults: Safety

10. DTG + 3TC vs DTG + TDF/FTC in Treatment-Naive Adults With HIV-1 Infection: GEMINI Efficacy Subgroup Analysis

11. DTG + 3TC vs DTG + TDF/FTC in Treatment-Naive Adults With HIV-1 Infection: GEMINI Subgroup Analysis of Discontinuations

12. DTG + 3TC vs DTG + TDF/FTC in Treatment-Naive Adults With HIV-1 Infection: GEMINI Safety Subgroup Analysis

13. Meta-Analysis Assessing Dual Therapy With PI/r + 3TC or PI/r + TDF

14. Meta-Analysis Assessing Dual Therapy With PI/r + 3TC or PI/r + TDF (Cont.)

15. Choosing a Dual Therapy Regimen

16. Selecting the Appropriate Patients for Dual Therapy Regimens

17. Comparable Viral Decay With DTG + 3TC vs DTG-Based Triple Therapy

18. Residual Viremia After Switch to DTG + 3TC

19. Ongoing Questions Regarding Dual Therapy

20. BMD in Virologically Suppressed Patients Aged ≥ 60 Years Switched From TDF- to TAF-Containing Regimens

21. Safety and Efficacy of Fostemsavir in Heavily Treatment-Experienced Patients: BRIGHTE

22. Safety and Efficacy of Fostemsavir in Heavily Treatment-Experienced Patients: BRIGHTE (Cont.)

23. Increases in Lipid Profile After Switch From TDF to TAF: Is It Clinically Relevant?

24. Increases in Lipid Profile After Switch From TDF to TAF: Is It Clinically Relevant? (Cont.)

25. Significant Weight Gain After Switch to DTG From a PI/r

26. Overview on Cure Research

27. STIs in Individuals Using PrEP

28. PrEP: In General and in Europe

29. Top 10 DDIs With ARVs

30. Top 10 DDIs With ARVs (Cont.)

31. Mental Health in PLWHIV

32. Program Conclusions

33. Program Conclusions (Cont.)

34. Abbreviations

35. Abbreviations (cont)

36. Abbreviations (cont)

37. Abbreviations (cont)